JP2018525381A5 - - Google Patents

Download PDF

Info

Publication number
JP2018525381A5
JP2018525381A5 JP2018506182A JP2018506182A JP2018525381A5 JP 2018525381 A5 JP2018525381 A5 JP 2018525381A5 JP 2018506182 A JP2018506182 A JP 2018506182A JP 2018506182 A JP2018506182 A JP 2018506182A JP 2018525381 A5 JP2018525381 A5 JP 2018525381A5
Authority
JP
Japan
Prior art keywords
protein
cell
nucleic acid
cell permeable
permeable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2018506182A
Other languages
English (en)
Japanese (ja)
Other versions
JP7104462B2 (ja
JP2018525381A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2016/045817 external-priority patent/WO2017024238A1/en
Publication of JP2018525381A publication Critical patent/JP2018525381A/ja
Publication of JP2018525381A5 publication Critical patent/JP2018525381A5/ja
Priority to JP2021109873A priority Critical patent/JP7260596B2/ja
Application granted granted Critical
Publication of JP7104462B2 publication Critical patent/JP7104462B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2018506182A 2015-08-06 2016-08-05 細胞透過性タンパク質-抗体コンジュゲートおよび使用方法 Active JP7104462B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2021109873A JP7260596B2 (ja) 2015-08-06 2021-07-01 細胞透過性タンパク質-抗体コンジュゲートおよび使用方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562202006P 2015-08-06 2015-08-06
US62/202,006 2015-08-06
PCT/US2016/045817 WO2017024238A1 (en) 2015-08-06 2016-08-05 Cell penetrating protein-antibody conjugates and methods of use

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2021109873A Division JP7260596B2 (ja) 2015-08-06 2021-07-01 細胞透過性タンパク質-抗体コンジュゲートおよび使用方法

Publications (3)

Publication Number Publication Date
JP2018525381A JP2018525381A (ja) 2018-09-06
JP2018525381A5 true JP2018525381A5 (https=) 2019-09-12
JP7104462B2 JP7104462B2 (ja) 2022-07-21

Family

ID=57943680

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2018506182A Active JP7104462B2 (ja) 2015-08-06 2016-08-05 細胞透過性タンパク質-抗体コンジュゲートおよび使用方法
JP2021109873A Active JP7260596B2 (ja) 2015-08-06 2021-07-01 細胞透過性タンパク質-抗体コンジュゲートおよび使用方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2021109873A Active JP7260596B2 (ja) 2015-08-06 2021-07-01 細胞透過性タンパク質-抗体コンジュゲートおよび使用方法

Country Status (7)

Country Link
US (2) US11661463B2 (https=)
EP (1) EP3331543A4 (https=)
JP (2) JP7104462B2 (https=)
CN (2) CN108135958B (https=)
AR (1) AR105642A1 (https=)
TW (1) TW201718023A (https=)
WO (1) WO2017024238A1 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201718023A (zh) * 2015-08-06 2017-06-01 世代好公司 細胞滲透性蛋白質-抗體結合物及使用方法
CN108866635B (zh) * 2017-05-09 2021-11-26 安升(上海)医药科技有限公司 多特异性蛋白药物及其文库、以及制备方法和应用
CN111093710A (zh) * 2017-07-13 2020-05-01 希望之城 硫代磷酸酯缀合的肽及其使用方法
WO2019125033A1 (ko) * 2017-12-22 2019-06-27 (주)로피바이오 세포 내 침투능을 갖는 항 stat3 이중특이 항체 및 이를 포함하는 약학적 조성물
KR102526768B1 (ko) * 2017-12-22 2023-04-27 주식회사 로피바이오 세포 내 침투능을 갖는 항 stat3 이중특이 항체
KR102256985B1 (ko) * 2019-06-25 2021-06-03 주식회사 로피바이오 항 stat3 특이 항체 및 이를 포함하는 약학적 조성물
WO2021237160A2 (en) * 2020-05-22 2021-11-25 City Of Hope Phosphorothioate nucleic acid conjugates including dna editing enzymes
WO2024091824A1 (en) 2022-10-26 2024-05-02 Ada Forsyth Institute, Inc. Differentiation and reprogramming of chondrocyte
EP4634373A1 (en) 2022-12-16 2025-10-22 University of Rochester Repairment of barrier dysfunction in esophagus

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2413974A1 (fr) 1978-01-06 1979-08-03 David Bernard Sechoir pour feuilles imprimees par serigraphie
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
EP0173494A3 (en) 1984-08-27 1987-11-25 The Board Of Trustees Of The Leland Stanford Junior University Chimeric receptors by dna splicing and expression
US4911920A (en) 1986-07-30 1990-03-27 Alcon Laboratories, Inc. Sustained release, comfort formulation for glaucoma therapy
US5034506A (en) 1985-03-15 1991-07-23 Anti-Gene Development Group Uncharged morpholino-based polymers having achiral intersubunit linkages
US5235033A (en) 1985-03-15 1993-08-10 Anti-Gene Development Group Alpha-morpholino ribonucleoside derivatives and polymers thereof
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
FR2588189B1 (fr) 1985-10-03 1988-12-02 Merck Sharp & Dohme Composition pharmaceutique de type a transition de phase liquide-gel
JPS63501765A (ja) 1985-11-01 1988-07-21 インタ−ナショナル、ジェネティック、エンジニアリング インコ−ポレ−テッド 抗体遺伝子のモジュ−ル組立体、それにより産生された抗体及び用途
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
ES2096590T3 (es) 1989-06-29 1997-03-16 Medarex Inc Reactivos biespecificos para la terapia del sida.
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
DE69132709T2 (de) 1990-06-29 2002-06-20 Large Scale Biology Corp., Vacaville Melaninproduktion durch transformierte mikroorganismen
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
ATE300615T1 (de) 1990-08-29 2005-08-15 Genpharm Int Transgene mäuse fähig zur produktion heterologer antikörper
ATE141502T1 (de) 1991-01-15 1996-09-15 Alcon Lab Inc Verwendung von karrageenan in topischen ophthalmologischen zusammensetzungen
US5212162A (en) 1991-03-27 1993-05-18 Alcon Laboratories, Inc. Use of combinations gelling polysaccharides and finely divided drug carrier substrates in topical ophthalmic compositions
WO1993008829A1 (en) 1991-11-04 1993-05-13 The Regents Of The University Of California Compositions that mediate killing of hiv-infected cells
US5777085A (en) 1991-12-20 1998-07-07 Protein Design Labs, Inc. Humanized antibodies reactive with GPIIB/IIIA
US6210671B1 (en) 1992-12-01 2001-04-03 Protein Design Labs, Inc. Humanized antibodies reactive with L-selectin
JP2002531466A (ja) 1998-12-01 2002-09-24 プロテイン デザイン ラブス, インコーポレイテッド γ−インターフェロンに対するヒト化抗体
CA2633063A1 (en) 2005-12-16 2007-06-21 Diatos Cell penetrating peptide conjugates for delivering of nucleic acids intocells
US20100239504A1 (en) * 2007-07-17 2010-09-23 The General Hospital Corporation Imaging nucleic acid binding proteins
EP2090584A1 (en) * 2008-02-13 2009-08-19 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Identification of a novel cysteine-rich cell penetrating peptide
WO2009126933A2 (en) * 2008-04-11 2009-10-15 Alnylam Pharmaceuticals, Inc. Site-specific delivery of nucleic acids by combining targeting ligands with endosomolytic components
CN103221549A (zh) * 2010-08-31 2013-07-24 默沙东公司 用于递送寡核苷酸的新型简单化学实体和方法
EP2797634A4 (en) 2011-12-29 2015-08-05 Moderna Therapeutics Inc MODIFIED MRNAS FOR THE CODING OF CELL-PENETRATING POLYPEPTIDES
CN108148838A (zh) * 2012-05-22 2018-06-12 奥利克斯医药有限公司 具有细胞内穿透能力的诱导rna干扰的核酸分子及用途
CN111437395A (zh) * 2013-08-29 2020-07-24 希望之城 细胞穿透缀合物及其使用方法
AU2016206475B2 (en) * 2015-01-16 2021-11-04 City Of Hope Cell penetrating antibodies
TW201718023A (zh) * 2015-08-06 2017-06-01 世代好公司 細胞滲透性蛋白質-抗體結合物及使用方法

Similar Documents

Publication Publication Date Title
JP2018525381A5 (https=)
JP2021167329A5 (https=)
JP2018525001A5 (https=)
JP2021502810A5 (https=)
JP2018505870A5 (https=)
JP2021531826A5 (https=)
JP2014502955A5 (https=)
JP2016116536A5 (https=)
RU2019102009A (ru) Специфические антитела к pd-l1 и способы их применения
JP2010540453A5 (https=)
JP2020502271A5 (https=)
JP2021524268A5 (https=)
JP2012521217A5 (https=)
HRP20211710T1 (hr) Konjugacija specifična za mjesto spajanja lijekova za povezivanje s protutijelima i konjugati protutijela u lijeku koji nastaje kao rezultat
JP2017529067A5 (https=)
JP2021524275A5 (https=)
JP2021152022A5 (https=)
JP2012533587A5 (https=)
JP2016536342A5 (https=)
JP2020513855A5 (https=)
JPWO2020031936A5 (https=)
JP2020524675A5 (https=)
RU2015100231A (ru) Способ отбора и получения селективных и мультиспецифических терапевтических молекул с заданными свойствами, включающих по меньшей мере две различные нацеливающие группировки, и их применения
JP2021524270A5 (https=)
JP2018530331A5 (https=)